Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's

Summit Therapeutics shares rose as much as 7% premarket after ivonescimab, partnered with Akeso, helped advanced lung cancer patients live 15% longer than BeOne Medicines' Tevimbra. The readout is a positive clinical efficacy signal for Summit's cancer therapy and supports the investment case. The move is likely stock-specific rather than broad market-moving.

Analysis

Summit Therapeutics shares rose as much as 7% premarket after ivonescimab, partnered with Akeso, helped advanced lung cancer patients live 15% longer than BeOne Medicines' Tevimbra. The readout is a positive clinical efficacy signal for Summit's cancer therapy and supports the investment case. The move is likely stock-specific rather than broad market-moving.